Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01780545 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
A Phase 2 study, sponsored by Noah Hahn, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT01780545 is a Phase 2 study that has completed, run by Noah Hahn, M.D.. The registered enrollment target is 200 participants.
The verdict
NCT01780545, a Phase 2 study, has completed, sponsored by Noah Hahn, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense oligonucleotide (ASO), in combination with docetaxel can prolong survival time compared to docetaxel alone in participants with locally advanced or metastatic urothelial carcinoma (UC) that are relapsed or refractory after receiving a platinum-containing regimen.
Interventions
- DRUG Docetaxel
- DRUG OGX-427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01780545
The ClinicalTrials.gov registry entry for NCT01780545 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noah Hahn, M.D., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01780545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01780545 about?
NCT01780545 is a clinical study titled "Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer". This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense oligonucleotide (ASO), in combination with docetaxel can prolong survival time compared to docetaxel alone in participants ...
What is the current status of trial NCT01780545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2013-04. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01780545?
The interventions under investigation include: Docetaxel (DRUG), OGX-427 (DRUG).
Who is sponsoring clinical trial NCT01780545?
This trial is sponsored by Noah Hahn, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.